Antioxidants halt axonal degeneration in a mouse model of X‐adrenoleukodystrophy
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective: Axonal degeneration is a main contributor to disability in progressive neurodegenerative diseases in which oxidative stress is often identified as a pathogenic factor. We aim to demonstrate that antioxidants are able to improve axonal degeneration and locomotor deficits in a mouse model of X‐adrenoleukodystrophy (X‐ALD). Methods: X‐ALD is a lethal disease caused by loss of function of the ABCD1 peroxisomal transporter of very long chain fatty acids (VLCFA). The mouse model for X‐ALD exhibits a late onset neurological phenotype with locomotor disability and axonal degeneration in spinal cord resembling the most common phenotype of the disease, adrenomyeloneuropathy (X‐AMN). Recently, we identified oxidative damage as an early event in life, and the excess of VLCFA as a generator of radical oxygen species (ROS) and oxidative damage to proteins in X‐ALD. Results: Here, we prove the capability of the antioxidants N‐acetyl‐cysteine, α‐lipoic acid, and α‐tocopherol to scavenge VLCFA‐dependent ROS generation in vitro. Furthermore, in a preclinical setting, the cocktail of the 3 compounds reversed: (1) oxidative stress and lesions to proteins, (2) immunohistological signs of axonal degeneration, and (3) locomotor impairment in bar cross and treadmill tests. Interpretation: We have established a direct link between oxidative stress and axonal damage in a mouse model of neurodegenerative disease. This conceptual proof of oxidative stress as a major disease‐driving factor in X‐AMN warrants translation into clinical trials for X‐AMN, and invites assessment of antioxidant strategies in axonopathies in which oxidative damage might be a contributing factor. Ann Neurol 2011;
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Free radical-induced damage to DNA: mechanisms and measurement
Dizdaroglu, M., Jaruga, P., Birincioglu, M., & Rodriguez, H. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00826-2 · Cited by 953
Moser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Dietary Antioxidants and the Long-term Incidence of Age-Related Macular Degeneration
Tan, J. S. L., Wang, J. J., Flood, V., Rochtchina, E., Smith, W., & Mitchell, P. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.083 · Cited by 381
Hettema, E. H., van Roermund, C. W., Distel, B., van den Berg, M., Vilela, C., Rodrigues‐Pousada, C., Wanders, R. J., & Tabak, H. F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00755.x · Cited by 323
A mouse model for X-linked adrenoleukodystrophy
Lu, J.-F., Lawler, A. M., Watkins, P. A., Powers, J. M., Moser, A. B., Moser, H. W., & Smith, K. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9366 · Cited by 293 · cited 1×
“Mouse Breeding The generation and genotyping of Abcd1 mice have been previously described.(16,17,25) Mice used for experiments were of a pure”
MethodBeneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders
Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., & Tarnopolsky, M. A. (2007) · Muscle & Nerve · doi:10.1002/mus.20688 · Cited by 255
The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl–CoA esters
van Roermund, C. W. T., Visser, W. F., IJlst, L., van Cruchten, A., Boek, M., Kulik, W., Waterham, H. R., & Wanders, R. J. A. (2008) · The FASEB Journal · doi:10.1096/fj.08-110866 · Cited by 233 · cited 1×
“The gene mutated in the disease encodes the ABCD1 protein, an adenosine triphosphate-binding cassette peroxisomal transporter involved in the import of very long chain fatty acids (C 22:0) and VLCFA-CoA esters into the peroxisome for degradation.(14,15) Defective function of the ABCD1 transporter leads to VLCFA accumu…”
BackgroundPujol, A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.499 · Cited by 214 · cited 3×
“Classical inactivation of ABCD1 in the mouse results in late onset neurodegeneration with axonopathy in the spinal cord that, in the absence of inflammatory demyelination in the brain, resembles the most frequent X-ALD phenotype or adrenomyeloneuropathy.(16,17) Oxidative damage has been evidenced in postmortem brain s…”
BackgroundMethodSelf-citationEarly oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy
Fourcade, S., Lopez-Erauskin, J., Galino, J., Duval, C., Naudi, A., Jove, M., Kemp, S., Villarroya, F., Ferrer, I., Pamplona, R., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn085 · Cited by 214 · cited 9×
“The source of this oxidative damage is possibly related to the excess of saturated and unsaturated VLCFA, shown to generate both free radicals and oxidative damage to proteins in vitro.(20,21) In the present study, we set out to test the potential of 3 well-known antioxidants, a-tocopherol, N-acetylcysteine (NAC), and…”
BackgroundMethodResultInfluentialSelf-citationPujol, A., Ferrer, I., Camps, C., Metzger, E., Hindelang, C., Callizot, N., Ruiz, M., Pàmpols, T., Giròs, M., & Mandel, J. L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh323 · Cited by 201 · cited 6×
“This is accompanied by scattered myelin debris, as revealed by Sudan black, and astrocytosis and microgliosis, as identified with glial fibrillary acidic protein (GFAP) and lectin staining, respectively, without signs of apoptosis (see Fig 3D–S and Supplementary Table).(16) The first abnormal deposition of synaptophys…”
BackgroundMethodInfluentialSelf-citationGeneral aspects and neuropathology of X-linked adrenoleukodystrophy
Ferrer, I., Aubourg, P., & Pujol, A. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00390.x · Cited by 139
Self-citationNmnat delays axonal degeneration caused by mitochondrial and oxidative stress
Press, C., & Milbrandt, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0525-08.2008 · Cited by 137
Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question
Armstrong, J. S., Khdour, O., & Hecht, S. M. (2010) · The FASEB Journal · doi:10.1096/fj.09-143222 · Cited by 107 · cited 1×
“However, exceptions can be made when the causality link between oxidative stress and disease is well established, as is the case for Friedreich ataxia, a rare disease caused by mutations in frataxin, a mitochondrial ferrosulfur protein involved in ROS homeostasis.(51) Friedreich patients exhibit spinocerebellar ataxia…”
BackgroundFerrer, I., Kapfhammer, J. P., Hindelang, C., Kemp, S., Troffer-Charlier, N., Broccoli, V., Callyzot, N., Mooyer, P., Selhorst, J., Vreken, P., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi384 · Cited by 106 · cited 5×
“Also, locomotor testing is facilitated in this model, as the first signs of neurological involvement can be seen at 15 months of age, using the bar cross test.(38) For the sake of starting the treatment on symptomatic mice, we re-evaluated locomotor skills by using the bar cross(38) and treadmill tests,(39) starting a…”
BackgroundMethodInfluentialSelf-citationA key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis
Fourcade, S., Ruiz, M., Camps, C., Schlüter, A., Houten, S. M., Mooyer, P. A. W., Pàmpols, T., Dacremont, G., Wanders, R. J. A., Giròs, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90736.2008 · Cited by 104
Self-citationGilg, A. G., Singh, A. K., & Singh, I. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.12.1063 · Cited by 66
Differential alterations in antioxidant capacity in cells from Alzheimer patients
Gibson, G. E., Zhang, H., Sheu, K.-F. R., & Park, L. C. H. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00057-0 · Cited by 44
Cited by
Role of peroxisomes in ros/rns-metabolism: Implications for human disease
Fransen, M., Nordgren, M., Wang, B., & Apanasets, O. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.12.001 · Cited by 644
Wallerian degeneration: an emerging axon death pathway linking injury and disease
Conforti, L., Gilley, J., & Coleman, M. P. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3680 · Cited by 611
Engelen, M., Kemp, S., de Visser, M., van Geel, B. M., Wanders, R. J., Aubourg, P., & Poll-The, B. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-51 · Cited by 562
X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects
Kemp, S., Berger, J., & Aubourg, P. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.03.012 · Cited by 283
“This notion is supported by the observation that antioxidants reduce markers for oxidative stress and axonal degeneration in the spinal cord of Abcd1 knockout mice [88].”
Karuppagounder, S. S., Alin, L., Chen, Y., Brand, D., Bourassa, M. W., Dietrich, K., Wilkinson, C. M., Nadeau, C. A., Kumar, A., Perry, S., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25356 · Cited by 298
Metadata
- Authors
- López‐Erauskin, J., Fourcade, S., Galino, J., Ruiz, M., Schlüter, A., Naudi, A., Jove, M., Portero‐Otin, M., Pamplona, R., Ferrer, I., & Pujol, A.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-07
- Volume
- 70
- Issue
- 1
- Pages
- 84-92
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2039294355
- Cited by
- 135
- References
- 19
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.